Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Deepa Bisht

Deepa Bisht

National JALMA Institute for Leprosy & Other Mycobacterial Diseases (ICMR), India

Title: Exploring aminoglycosides resistance in Mycobacterium tuberculosis isolates by proteomics and mass spectrometry

Biography

Biography: Deepa Bisht

Abstract

Tuberculosis (TB) caused by the pathogen Mycobacterium tuberculosis (MTB) still remains a major global public health issue. India is a country burdened with high TB. Increasing incidences of multidrug-resistant strains and of co-infection with HIV, urgently demands better control measures. Aminoglycosides are broad spectrum antibiotics and are an important component of any antituberculosis therapy regimen and drugs of choice especially for category II patients. Streptomycin (SM), kanamycin (KM) and amikacin (AK) are the key aminoglycosides drugs against TB and resistance to these severely affects the options for treatment. They inhibit protein synthesis by interacting with steps of translation. Several explanations have been put forward for aminoglycosides resistance but still our understanding is fragmentary. As proteins manifest most of the biological processes, these are attractive targets for developing drugs, immunodiagnostics or therapeutics. Two-dimensional gel electrophoresis is an extremely powerful tool to dissect multiprotein complexes. Whole proteome analysis of aminoglycosides susceptible and resistant isolates by two-dimensional gel electrophoresis and their identification by mass spectrometry and bioinformatics tools have been carried out. Some proteins were found to be overexpressed in resistant isolates. Few of these were identified as hypothetical proteins. In silico docking analysis showed significant interactions of these drugs with hypothetical proteins. Characterization of hypothetical proteins may provide information about new targets against resistant TB or some new more effective vaccine candidates.